Floatz logo

ADVICOR COMPONENT NIACIN

Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

AHS Cancer Control AlbertaSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

40 Active assets in the Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
Nivolumab
Neonc Technologies, Inc.
Phase 2B
Ipilimumab
Neonc Technologies, Inc.
Phase 2B
Cerebraca Wafer
Everfront Biotech Co., Ltd.
Phase 2/3B

View all 44 →

Same molecule, other indications

ADVICOR COMPONENT NIACIN is also rated in:

inherited lipid metabolism disorderDormant
BBB
Indicative ·
73 / 100
View asset →
coronary artery disorderDormant
BBB
Indicative ·
73 / 100
View asset →
stroke disorderDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →